| dc.creator | Spanos, K. | en |
| dc.creator | Giannoukas, A. D. | en |
| dc.date.accessioned | 2015-11-23T10:48:05Z | |
| dc.date.available | 2015-11-23T10:48:05Z | |
| dc.date.issued | 2015 | |
| dc.identifier | 10.1016/j.ejvs.2014.11.019 | |
| dc.identifier.issn | 1078-5884 | |
| dc.identifier.uri | http://hdl.handle.net/11615/33240 | |
| dc.source.uri | <Go to ISI>://WOS:000352332500022 | |
| dc.subject | COST-EFFECTIVENESS | en |
| dc.subject | WARFARIN | en |
| dc.subject | Surgery | en |
| dc.subject | Peripheral Vascular Disease | en |
| dc.title | Re: 'Kakkos et al. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials' | en |
| dc.type | journalArticle | en |
